AU2001255709A1 - Acylated cyclodextrin guest inclusion complexes - Google Patents

Acylated cyclodextrin guest inclusion complexes

Info

Publication number
AU2001255709A1
AU2001255709A1 AU2001255709A AU5570901A AU2001255709A1 AU 2001255709 A1 AU2001255709 A1 AU 2001255709A1 AU 2001255709 A AU2001255709 A AU 2001255709A AU 5570901 A AU5570901 A AU 5570901A AU 2001255709 A1 AU2001255709 A1 AU 2001255709A1
Authority
AU
Australia
Prior art keywords
inclusion complex
acylated cyclodextrin
molecule
guest molecule
inclusion complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001255709A
Inventor
Charles M. Buchanan
Jozef Szejtli
Lajos Szente
Maria Vikmon
Matthew D. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastman Chemical Co
Original Assignee
Eastman Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastman Chemical Co filed Critical Eastman Chemical Co
Publication of AU2001255709A1 publication Critical patent/AU2001255709A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention is directed to a method of making an inclusion complex comprising an acylated cyclodextrin host molecule and a guest molecule, wherein the method comprises the steps of: a)contacting the acylated cyclodextrin host molecule and the guest molecule to form an inclusion complex; and b) precipitating the inclusion complex in an aqueous medium. The present invention is further directed to an inclusion complex comprising an acylated cyclodextrin host molecule and a guest molecule, wherein the guest molecule comprises from about 2% (wt.) to about 15% (wt.) of the inclusion complex. Moreover, the present invention relates to a composition comprising a polymer and an inclusion complex, wherein the inclusion complex comprises an acylated cyclodextrin host molecule and a guest molecule and medical devices and solid pharmaceutical compositions comprised thereof.
AU2001255709A 2000-05-11 2001-04-26 Acylated cyclodextrin guest inclusion complexes Abandoned AU2001255709A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20350000P 2000-05-11 2000-05-11
US60/203,500 2000-05-11
US20571500P 2000-05-19 2000-05-19
US60/205,715 2000-05-19
PCT/US2001/013499 WO2001085218A2 (en) 2000-05-11 2001-04-26 Acylated cyclodextrin guest inclusion complexes

Publications (1)

Publication Number Publication Date
AU2001255709A1 true AU2001255709A1 (en) 2001-11-20

Family

ID=26898664

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001255709A Abandoned AU2001255709A1 (en) 2000-05-11 2001-04-26 Acylated cyclodextrin guest inclusion complexes

Country Status (7)

Country Link
US (2) US20020025946A1 (en)
EP (1) EP1280559B1 (en)
JP (1) JP2003532757A (en)
AT (1) ATE319480T1 (en)
AU (1) AU2001255709A1 (en)
DE (1) DE60117777T2 (en)
WO (1) WO2001085218A2 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144880B2 (en) * 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
EP2062583B1 (en) 1999-04-30 2012-12-26 The Regents of the University of Michigan Therapeutic applications of pro-apoptotic benzodiazepines
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
JP2003321474A (en) * 2002-04-30 2003-11-11 Kentetsuku:Kk Clathrate compound
CA2489282A1 (en) * 2002-06-10 2003-12-18 Leo Rubin Medical device for intra-lumenal delivery of pharmaceutical agents
US7785512B1 (en) 2003-07-31 2010-08-31 Advanced Cardiovascular Systems, Inc. Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices
US7645474B1 (en) * 2003-07-31 2010-01-12 Advanced Cardiovascular Systems, Inc. Method and system of purifying polymers for use with implantable medical devices
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
AU2004312096A1 (en) 2003-12-31 2005-07-21 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
WO2005088655A1 (en) * 2004-03-12 2005-09-22 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A magnetoresistive medium
US20050208093A1 (en) 2004-03-22 2005-09-22 Thierry Glauser Phosphoryl choline coating compositions
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
FR2877846B1 (en) * 2004-11-15 2008-12-05 Univ Lille Sciences Tech BIOMATERIAL CARRIERS OF CYCLODEXTRINS WITH IMPROVED ABSORPTION PROPERTIES AND PROGRESSIVE AND DELAYED RELEASE OF THERAPEUTIC MOLECULES
EP1845996A4 (en) * 2005-01-03 2009-04-29 Univ Michigan Compositions and methods relating to novel compounds and targets thereof
WO2007053193A2 (en) 2005-06-01 2007-05-10 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
DE102005033543A1 (en) * 2005-07-14 2007-01-18 Grünenthal GmbH A fragrance-containing transdermal therapeutic system
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
CA2628193C (en) 2005-11-01 2012-08-14 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
WO2007058247A1 (en) * 2005-11-17 2007-05-24 Daikin Industries, Ltd. Clathrate compound of fluoropolyether molecule
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070178050A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an increased lung depositon
JP2009526860A (en) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー Stable corticosteroid mixture
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
KR100718280B1 (en) * 2006-06-08 2007-05-16 재단법인서울대학교산학협력재단 Poly(vinyl chloride) product containing cyclodextrin derivatives with suppression of the migration of plasticizer and manufacturing method thereof
MX2008015488A (en) 2006-06-09 2009-02-12 Univ Michigan Compositions and methods relating to novel compounds and targets thereof.
US10149910B2 (en) * 2007-03-01 2018-12-11 The Procter & Gamble Plaza Compositions and/or articles comprising cyclodextrin complexing material
US11090250B2 (en) 2007-03-01 2021-08-17 The Procter & Gamble Company Compositions and/or articles comprising cyclodextrin complexing material
MX2009009645A (en) 2007-03-09 2009-11-19 Univ Michigan Compositions and methods relating to novel compounds and targets thereof.
JP5182661B2 (en) * 2007-07-31 2013-04-17 株式会社ネオス Solid oil and method for producing solid oil
KR100929920B1 (en) * 2007-09-05 2009-12-04 주식회사 마크로케어 Method for preparing clathrate containing hydrophobic physiologically active ingredient in cyclodextrin and derivatives thereof and use of clathrate prepared thereby
WO2009031026A2 (en) * 2007-09-06 2009-03-12 Combino Pharm, S.L. Novel pharmaceutical compositions
CA2698248C (en) 2007-09-14 2017-08-29 The Regents Of The University Of Michigan Phenyl acyl guanidine derivatives as f1f0-atpase inhibitors and the use thereof
AU2008323945B2 (en) 2007-11-06 2013-11-28 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
US8040246B2 (en) * 2007-12-04 2011-10-18 Avaya Inc. Systems and methods for facilitating a first response mission at an incident scene
AU2009291632B2 (en) 2008-09-11 2013-04-04 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
WO2011035124A1 (en) 2009-09-18 2011-03-24 The Regents Of The University Of Michigan Benzodiazepinone compounds and methods of treatment using same
WO2011062766A2 (en) 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
CA2780333C (en) 2009-11-17 2016-05-24 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
EP2635121B1 (en) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compounds and methods for the treatment of cancer
US10328152B2 (en) 2011-06-16 2019-06-25 Nayan Patel Method for stabilization and delivery of therapeutic molecules
JP5906518B2 (en) * 2011-08-11 2016-04-20 地方独立行政法人鳥取県産業技術センター Method for producing cyclodextrin inclusion compound-containing composition
PL3253208T3 (en) 2015-02-02 2021-11-08 Mei Pharma, Inc. Combination therapies for use in the treatment of breast cancer
EP3509562B1 (en) 2016-09-06 2021-06-23 The Procter & Gamble Company Aerosol compositions
BR112019004271B8 (en) 2016-09-06 2022-09-20 Procter & Gamble DEODORANT AND ANTIPERSPIRANT COMPOSITIONS
WO2019177558A1 (en) * 2018-03-16 2019-09-19 T.C. Istanbul Medipol Universitesi Inclusion complexes suitable for use as a histotripsy agent
JP7323887B2 (en) * 2019-02-28 2023-08-09 国立大学法人北海道大学 cellulose acetate film
KR20220110730A (en) * 2019-10-21 2022-08-09 이솔레이트 엘티디 Ultrafine compound and preparation thereof
CN114917365B (en) * 2022-06-09 2023-12-08 上海彤颜实业有限公司 WGX50 cyclodextrin inclusion compound, preparation method, solubility and cyclodextrin inclusion rate determination method
CN114886877B (en) * 2022-06-16 2024-02-02 北京海泰天正医药科技有限公司 Olanzapine Ping Fu sittin compound oral solution film and preparation method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU183430B (en) * 1981-05-12 1984-05-28 Chinoin Gyogyszer Es Vegyeszet Process for producing cyclodextrine inclusion complexes of n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine or n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine-hydrochloride
JPS5921613A (en) * 1982-07-28 1984-02-03 Takeda Chem Ind Ltd Pharmaceutical preparation for rectum administration
US6146358A (en) * 1989-03-14 2000-11-14 Cordis Corporation Method and apparatus for delivery of therapeutic agent
HU211648A9 (en) * 1990-03-28 1995-12-28 Chinoin Gyogyszer Es Vegyeszet Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same
FR2692168B1 (en) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Preparation and use of new dispersible colloidal systems based on cyclodextrin, in the form of nanospheres.
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
DE4414128A1 (en) * 1994-04-22 1995-10-26 Consortium Elektrochem Ind Partially acylated beta-cyclodextrins
JPH10194996A (en) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv Acylated cyclodextrin-containing pharmaceutical composition

Also Published As

Publication number Publication date
WO2001085218A2 (en) 2001-11-15
ATE319480T1 (en) 2006-03-15
JP2003532757A (en) 2003-11-05
WO2001085218A3 (en) 2002-09-12
US20040063663A1 (en) 2004-04-01
DE60117777D1 (en) 2006-05-04
US20020025946A1 (en) 2002-02-28
EP1280559B1 (en) 2006-03-08
EP1280559A2 (en) 2003-02-05
DE60117777T2 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
AU2001255709A1 (en) Acylated cyclodextrin guest inclusion complexes
CA2289202A1 (en) Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent
WO2001068144A3 (en) Biodegradable immunomodulatory formulations and methods for use thereof
CA2303498A1 (en) Dioxocyclopentyl hydroxamic acids
EP1158021A4 (en) Microgels and external preparations containing the same
KR870002842A (en) Containing Complexes of 7-Isopropoxy-Isoflavones Prepared from Cyclodextrins and Pharmacological Compositions and Preparations Containing the Active Ingredients
HK1089100A1 (en) Skin care composition comprising skin lightening agent
WO2002049590A3 (en) Antiperspirant products
DE69737834D1 (en) Film compositions of polymer for the production of capsules
EP2067487A3 (en) Immunomodulatory formulations and methods for use thereof
WO2003007985A3 (en) Capsular polysaccharide solubilisation and combination vaccines
AU2003273413A1 (en) Pharmaceutically active oligosaccharide conjugates
GEP20063917B (en) Pulmonary administration of chemically modified insulin
BR0211028A (en) Aqueous solution, method for forming drug and polymer combinations, pharmaceutical compositions, method for forming a pharmaceutical composition and product
EP1281722A4 (en) Hyaluronic acid gel, process for producing the same, and medical material containing the same
CA2311438A1 (en) Self-tanning mousse
CA2423096A1 (en) Low residue well treatment fluids and methods of use
AU3269397A (en) Oxidized oligosaccharides
TW200519129A (en) Biodegradable hyaluronic acid derivative, biodegradable polymeric micelle composition, and pharmaceutical or bioactive composition containing the micelle composition
MEP9309A (en) Novel oligosaccharides, preparation method and pharmaceutical compositions containing the same
JP2002080321A5 (en)
CZ16395A3 (en) Inclusion complexes of nimesulid salts of alkali metals and alkaline earth metals with cyclodextrins, process of their preparation and pharmaceutical compositions containing thereof
AU3252197A (en) Novel self-acid-doped highly conducting polythiophenes
EP0931545A3 (en) Droloxifene pharmaceutical compositions
MD1419G2 (en) Inclusion complex on SIN-1A and cyclodextrin base, pharmaceutical compositions and kits on base thereof, process for preparation of cyclodextrin inclussion complexes and method of treatment